New study shows atorvastatin cuts heart events in seniors but not overall disability
Research presented by the European Society of Cardiology finds that atorvastatin reduces major cardiovascular events by 30% in older adults without prior disease, while showing no clear benefit for disability-free survival.
The European Society of Cardiology released findings from a trial that enrolled 9,971 people aged 70 or older who had no history of cardiovascular disease, diabetes or dementia. Participants received either 40 mg of atorvastatin each day or a placebo, and were followed for a median of 5.9 years. The study showed a 30% reduction in major cardiovascular events—including cardiovascular death, non-fatal heart attack, stroke and coronary revascularisation—in the atorvastatin arm.
In contrast, the incidence of death, dementia or persistent physical disability did not differ meaningfully between the two groups. Adverse events related to muscle, liver and diabetes occurred more often among those taking the statin, but serious adverse events were uncommon, affecting 2.7% of both groups. Lead researcher Professor Sophia Zoungas highlighted the trial as the first large-scale investigation of primary-prevention statin use in this age group. The results address previous uncertainty about the risk-benefit balance of statins for older adults without established disease.
Why it matters
The findings clarify whether cholesterol-lowering drugs help seniors avoid heart attacks without extending healthy lifespan.
In this story
